Literature DB >> 11462005

Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.

C Fayolle1, A Osickova, R Osicka, T Henry, M J Rojas, M F Saron, P Sebo, C Leclerc.   

Abstract

CyaA, the adenylate cyclase toxin from Bordetella pertussis, can deliver its N-terminal catalytic domain into the cytosol of a large number of eukaryotic cells and particularly into professional antigen-presenting cells. We have previously identified within the primary structure of CyaA several permissive sites at which insertion of peptides does not alter the ability of the toxin to enter cells. This property has been exploited to design recombinant CyaA toxoids capable of delivering major histocompatibility complex (MHC) class I-restricted CD8(+) T-cell epitopes into antigen-presenting cells and to induce specific CD8(+) cytotoxic T-lymphocyte (CTL) responses in vivo. Here we have explored the capacity of the CyaA vector carrying several different CD8(+) T-cell epitopes to prime multiple CTL responses. The model vaccine consisted of a polyepitope made of three CTL epitopes from lymphocytic choriomeningitis virus (LCMV), the V3 region of human immunodeficiency virus gp120, and chicken ovalbumin, inserted at three different sites of the catalytic domain of genetically detoxified CyaA. Each of these epitopes was processed on delivery by CyaA and presented in vitro to specific T-cell hybridomas. Immunization of mice by CyaA toxoids carrying the polyepitope lead to the induction of specific CTL responses for each of the three epitopes, as well as to protection against a lethal viral challenge. Moreover, mice primed against the vector by mock CyaA or a recombinant toxoid were still able to develop strong CTL responses after subsequent immunization with a recombinant CyaA carrying a foreign CD8(+) CTL epitope. These results highlight the potency of the adenylate cyclase vector for induction of protective CTL responses with multiple specificity and/or broad MHC restriction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462005      PMCID: PMC114968          DOI: 10.1128/JVI.75.16.7330-7338.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.

Authors:  J D Ballard; R J Collier; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

2.  Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.

Authors:  S A Rosenberg; Y Zhai; J C Yang; D J Schwartzentruber; P Hwu; F M Marincola; S L Topalian; N P Restifo; C A Seipp; J H Einhorn; B Roberts; D E White
Journal:  J Natl Cancer Inst       Date:  1998-12-16       Impact factor: 13.506

3.  DNA-based immunization by in vivo transfection of dendritic cells.

Authors:  C Condon; S C Watkins; C M Celluzzi; K Thompson; L D Falo
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

4.  Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.

Authors:  N H Carbonetti; T J Irish; C H Chen; C B O'Connell; G A Hadley; U McNamara; R G Tuskan; G K Lewis
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

5.  A protein particle vaccine containing multiple malaria epitopes.

Authors:  S C Gilbert; M Plebanski; S J Harris; C E Allsopp; R Thomas; G T Layton; A V Hill
Journal:  Nat Biotechnol       Date:  1997-11       Impact factor: 54.908

6.  Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.

Authors:  S A Thomson; M A Sherritt; J Medveczky; S L Elliott; D J Moss; G J Fernando; L E Brown; A Suhrbier
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

7.  Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion.

Authors:  R E Toes; R C Hoeben; E I van der Voort; M E Ressing; A J van der Eb; C J Melief; R Offringa
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

8.  Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus.

Authors:  M F Saron; C Fayolle; P Sebo; D Ladant; A Ullmann; C Leclerc
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population.

Authors:  Q He; M K Viljanen; H Arvilommi; B Aittanen; J Mertsola
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

10.  Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells.

Authors:  G Karimova; C Fayolle; S Gmira; A Ullmann; C Leclerc; D Ladant
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more
  14 in total

1.  Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase.

Authors:  Jiina Loucká; Géraldine Schlecht; Jana Vodolánová; Claude Leclerc; Peter Sebo
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 2.  Bordetella adenylate cyclase toxin: a unique combination of a pore-forming moiety with a cell-invading adenylate cyclase enzyme.

Authors:  Jiri Masin; Radim Osicka; Ladislav Bumba; Peter Sebo
Journal:  Pathog Dis       Date:  2015-09-20       Impact factor: 3.166

3.  Nanobody-Antigen Conjugates Elicit HPV-Specific Antitumor Immune Responses.

Authors:  Andrew W Woodham; Ross W Cheloha; Jingjing Ling; Mohammad Rashidian; Stephen C Kolifrath; Maia Mesyngier; Joao N Duarte; Justin M Bader; Joseph G Skeate; Diane M Da Silva; W Martin Kast; Hidde L Ploegh
Journal:  Cancer Immunol Res       Date:  2018-05-23       Impact factor: 11.151

4.  Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen-presenting cells by the Bordetella RTX hemolysin moiety lacking the adenylyl cyclase domain.

Authors:  Jana Holubova; Jana Kamanova; Jiri Jelinek; Jakub Tomala; Jiri Masin; Martina Kosova; Ondrej Stanek; Ladislav Bumba; Jaroslav Michalek; Marek Kovar; Peter Sebo
Journal:  Infect Immun       Date:  2012-01-03       Impact factor: 3.441

5.  Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.

Authors:  Laurent Mascarell; Catherine Fayolle; Cécile Bauche; Daniel Ladant; Claude Leclerc
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Modular domain swapping among the bacterial cytotoxic necrotizing factor (CNF) family for efficient cargo delivery into mammalian cells.

Authors:  Elizabeth E Haywood; Mengfei Ho; Brenda A Wilson
Journal:  J Biol Chem       Date:  2018-01-25       Impact factor: 5.157

7.  A highly optimized DNA vaccine confers complete protective immunity against high-dose lethal lymphocytic choriomeningitis virus challenge.

Authors:  Devon J Shedlock; Kendra T Talbott; Christina Cress; Bernadette Ferraro; Steven Tuyishme; Karthik Mallilankaraman; Neil J Cisper; Matthew P Morrow; Stephan J Wu; Omkar U Kawalekar; Amir S Khan; Niranjan Y Sardesai; Karuppiah Muthumani; Hao Shen; David B Weiner
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

8.  Recognition of mycobacterial antigens delivered by genetically detoxified Bordetella pertussis adenylate cyclase by T cells from cattle with bovine tuberculosis.

Authors:  H Martin Vordermeier; Marcela Simsova; Katalin A Wilkinson; Robert J Wilkinson; R Glyn Hewinson; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

9.  High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.

Authors:  Sandra Hervas-Stubbs; Laleh Majlessi; Marcela Simsova; Jana Morova; Marie-Jesus Rojas; Clémence Nouzé; Priscille Brodin; Peter Sebo; Claude Leclerc
Journal:  Infect Immun       Date:  2006-06       Impact factor: 3.441

10.  Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.

Authors:  Susanne Tartz; Jana Kamanova; Marcela Simsova; Peter Sebo; Stefanie Bolte; Volker Heussler; Bernhard Fleischer; Thomas Jacobs
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.